Sihuan Pharmaceutical : VOLUNTARY ANNOUNCEMENT THE GROUP'S LIRAGLUTIDE HAS COMPLETED PHASE I CLINICAL STUDY FOR INDICATION OF WEIGHT LOSS

About this update from Sihuan Pharmaceutical Holdings Group Ltd.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Sihuan Pharmaceutical Holdings Group Ltd. ̬ᐑᔼᖹછٰණྠϞࠢʮ̡ (incorporated in Bermuda with limited liability) (Stock Code: 0460) VOLUNTARY ANNOUNCEMENT THE GROUP'S LIRAGLUTIDE HAS COMPLETED PHASE I CLINICAL STUDY FOR INDICATION OF WEIGHT LOSS The board of directors (the " Board ") of Sihuan Pharmaceutical Holdings Group Ltd. (the " Company ", together with its subsidiaries, the " Group ") is pleased to announce that the Group's liraglutide project, developed for the treatment of type 2 diabetes and obesity, has completed its Phase I clinical study and obtained preliminary bioequivalence results on pharmacokinetics and pharmacodynamics. The Group is currently in communication with the Phase III development programme for obesity and expect to enter Phase III clinical trial soon. Liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, is approved by the US Food and Drug Administration for the treatment of adults and people over 10 years of age with type 2 diabetes, and for reducing the risk of heart attack, stroke and cardiovascular death in people with type 2 diabetes, in addition to showing potential in clinical trials for weight loss and improvement of obesity-related comorbidities. In the People's Republic of China, Victoza (liraglutide), developed by Novo Nordisk, saw a significant volume release following its entry into the national health insurance list in 2017, with revenues reaching RMB926 million in 2019, up 70% year-on-year. According to disclosures by Novo Nordisk, its liraglutide weight loss product Saxenda achieved global sales of USD851 million in 2019, a growth rate of 47%, with the product being the main driver of its global growth. The Group's liraglutide product is expected to focus in the China market. This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product. By Order of the Board Sihuan Pharmaceutical Holdings Group Ltd. Dr. Che Fengsheng Chairman and Executive Director Hong Kong, 26 February 2021 As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Kim Jin Ha; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.

View stock analysis, news, and events for Sihuan Pharmaceutical Holdings Group Ltd.